# Telitacicept in Primary APS Patients

> **NCT05078710** · PHASE2 · TERMINATED · sponsor: **Peking Union Medical College Hospital** · enrollment: 20 (actual)

## Conditions studied

- Anti Phospholipid Syndrome

## Interventions

- **DRUG:** Telitacicept

## Key facts

- **NCT ID:** NCT05078710
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** There is no clear therapeutic effect among the enrolled patients for the time being.
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05078710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05078710, "Telitacicept in Primary APS Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05078710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*